https://stemcell.ucla.edu/news/ucla-based-startup-new-muscular-dystrophy-treatment-personal-mission
For UCLA-based startup, new muscular dystrophy treatment is a personal mission
Courtney Young helped develop the gene therapy at the heart of a biotech startup, MyoGene Bio, when she was a doctoral student at UCLA from 2013 to 2018. But...
muscular dystrophy treatmentstartup new
https://www.benzinga.com/general/biotech/24/12/42490072/solid-biosciences-positioned-for-next-gen-duchenne-muscular-dystrophy-treatment-success-analyst
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst -...
Dec 13, 2024 - Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway.
duchenne muscular dystrophynext gen
https://www.vyondys53.com/
VYONDYS 53 (golodirsen) | Duchenne Muscular Dystrophy Treatment
Vyondys 53, an FDA-approved Duchenne muscular dystrophy treatment for patients who have a genetic mutation in the dystrophin gene that can be treated by...
duchenne muscular dystrophytreatment
https://www.urmc.rochester.edu/conditions-and-treatments/muscular-dystrophy
Muscular Dystrophy | Rochester, NY | Expert Treatment | URochester Medicine
University of Rochester Medicine offers expert muscular dystrophy care with genetic testing, physical therapy, infusion therapy, and access to clinical trials.
muscular dystrophyrochester nyexperttreatmentmedicine
https://www.sciencedaily.com/releases/2008/03/080316161133.htm
New Treatment Strategy Possible For Muscular Dystrophy, Mouse Studies Show | ScienceDaily
An investigational antiviral drug currently undergoing human trials in Europe for treating hepatitis C infections may have potential to reduce muscle cell...
new treatmentmuscular dystrophystudies showstrategypossible
https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy
FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy...
FDA Approves Elevidys, a gene therapy for the treatment of pediatric patients 4 through 5 years of age with Duchenne muscular dystrophy (DMD) with a confirmed...